338 related articles for article (PubMed ID: 34359757)
1. Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia.
Vitale C; Boccellato E; Comba L; Jones R; Perutelli F; Griggio V; Coscia M
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359757
[TBL] [Abstract][Full Text] [Related]
2. NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications.
Sportoletti P; De Falco F; Del Papa B; Baldoni S; Guarente V; Marra A; Dorillo E; Rompietti C; Adamo FM; Ruggeri L; Di Ianni M; Rosati E
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206399
[TBL] [Abstract][Full Text] [Related]
3. Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia.
Griggio V; Perutelli F; Salvetti C; Boccellato E; Boccadoro M; Vitale C; Coscia M
Front Immunol; 2020; 11():594556. PubMed ID: 33312177
[TBL] [Abstract][Full Text] [Related]
4. Molecular Interactions Between Innate and Adaptive Immune Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications.
Haseeb M; Anwar MA; Choi S
Front Immunol; 2018; 9():2720. PubMed ID: 30542344
[TBL] [Abstract][Full Text] [Related]
5. Specific features of T- and NK-cellular immunity in chronic lymphocytic leukemia.
Pochtar EV; Lugovskaya SA; Naumova EV; Dmitrieva EA; Kostin AI; Dolgov VV
Klin Lab Diagn; 2021 Jun; 66(6):345-352. PubMed ID: 34105910
[TBL] [Abstract][Full Text] [Related]
6. Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis.
Gorini F; Azzimonti L; Delfanti G; Scarfò L; Scielzo C; Bertilaccio MT; Ranghetti P; Gulino A; Doglioni C; Di Napoli A; Capri M; Franceschi C; Caligaris-Cappio F; Ghia P; Bellone M; Dellabona P; Casorati G; de Lalla C
Blood; 2017 Jun; 129(26):3440-3451. PubMed ID: 28465341
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs.
Vitale C; Montalbano MC; Salvetti C; Boccellato E; Griggio V; Boccadoro M; Coscia M
Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 31979293
[TBL] [Abstract][Full Text] [Related]
8. Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers.
Walz JS; Kowalewski DJ; Backert L; Nelde A; Kohlbacher O; Weide B; Kanz L; Salih HR; Rammensee HG; Stevanović S
Leuk Lymphoma; 2018 Aug; 59(8):1949-1958. PubMed ID: 29295645
[TBL] [Abstract][Full Text] [Related]
9. A matter of debate in chronic lymphocytic leukemia: is the occurrence of autoimmune disorders an indicator of chronic lymphocytic leukemia therapy?
Strati P; Caligaris-Cappio F
Curr Opin Oncol; 2011 Sep; 23(5):455-60. PubMed ID: 21681094
[TBL] [Abstract][Full Text] [Related]
10. Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL.
Boeck CL; Amberger DC; Doraneh-Gard F; Sutanto W; Guenther T; Schmohl J; Schuster F; Salih H; Babor F; Borkhardt A; Schmetzer H
J Immunother; 2017; 40(6):224-248. PubMed ID: 28557814
[TBL] [Abstract][Full Text] [Related]
11. [News in therapeutic management of chronic lymphoid leukemia].
Michallet AS; Salles G; Coiffier B; Michallet M
Bull Cancer; 2005 Mar; 92(3):249-56. PubMed ID: 15820919
[TBL] [Abstract][Full Text] [Related]
12. T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword.
Vlachonikola E; Stamatopoulos K; Chatzidimitriou A
Front Immunol; 2020; 11():612244. PubMed ID: 33552073
[TBL] [Abstract][Full Text] [Related]
13. Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia.
Solman IG; Blum LK; Hoh HY; Kipps TJ; Burger JA; Barrientos JC; O'Brien S; Mulligan SP; Kay NE; Hillmen P; Byrd JC; Lal ID; Dean JP; Mongan A
Leuk Res; 2020 Oct; 97():106432. PubMed ID: 32911375
[TBL] [Abstract][Full Text] [Related]
14. Beyond bystanders: Myeloid cells in chronic lymphocytic leukemia.
Hanna BS; Öztürk S; Seiffert M
Mol Immunol; 2019 Jun; 110():77-87. PubMed ID: 29173971
[TBL] [Abstract][Full Text] [Related]
15. Etiopathogenesis and prognostic implications of autoimmune hemolytic anemia association with chronic lymphocytic leukemia B.
Oprea MM; Ivanescu AM; Colita A; Coles E; Momanu RC; Berbec N; Lupu AR
J Med Life; 2012; 5(Spec Issue):44-47. PubMed ID: 31803285
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of biological variables in B-cell chronic lymphocytic leukemia. Can we improve upon clinical parameters?
Molica S
Haematologica; 1997; 82(6):705-9. PubMed ID: 9499672
[TBL] [Abstract][Full Text] [Related]
17. Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T-cells in chronic lymphocytic leukemia.
Rissiek A; Schulze C; Bacher U; Schieferdecker A; Thiele B; Jacholkowski A; Flammiger A; Horn C; Haag F; Tiegs G; Zirlik K; Trepel M; Tolosa E; Binder M
Int J Cancer; 2014 Nov; 135(10):2370-9. PubMed ID: 24723150
[TBL] [Abstract][Full Text] [Related]
18. [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases].
Kardum-Skelin I; Planinc-Peraica A; Ostojić Kolonić S; Radić-Kristo D; Milas M; Vrhovac R; Sustercić D; Minigo H; Jaksić B
Acta Med Croatica; 2008 Oct; 62(4):351-64. PubMed ID: 19205412
[TBL] [Abstract][Full Text] [Related]
19. Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease.
Rodríguez-Vicente AE; Díaz MG; Hernández-Rivas JM
Cancer Genet; 2013 Mar; 206(3):49-62. PubMed ID: 23531595
[TBL] [Abstract][Full Text] [Related]
20. Ectonucleoside triphosphate diphosphohydrolase-1 (E-NTPDase1/CD39) as a new prognostic marker in chronic lymphocytic leukemia.
Abousamra NK; Salah El-Din M; Hamza Elzahaf E; Esmael ME
Leuk Lymphoma; 2015 Jan; 56(1):113-9. PubMed ID: 24684231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
